The Discounted Cash Flow (DCF) valuation of Basilea Pharmaceutica AG (BSLN.SW) is 74.53 CHF. With the latest stock price at 54.10 CHF, the upside of Basilea Pharmaceutica AG based on DCF is 37.8%.
Based on the latest price of 54.10 CHF and our DCF valuation, Basilea Pharmaceutica AG (BSLN.SW) is a buy. buying BSLN.SW stocks now will result in a potential gain of 37.8%.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 7.6% | 6.3% |
| Long-term Growth Rate | 0.5% - 1.5% | 1.0% |
| Fair Price | 58.29 - 107.22 | 74.53 |
| Upside | 7.8% - 98.2% | 37.8% |